HighPoint Advisor Group LLC Makes New $185,000 Investment in Autolus Therapeutics plc (NASDAQ:AUTL)

HighPoint Advisor Group LLC bought a new stake in Autolus Therapeutics plc (NASDAQ:AUTL) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 78,620 shares of the company’s stock, valued at approximately $185,000.

Several other institutional investors also recently modified their holdings of the business. Wellington Management Group LLP grew its stake in shares of Autolus Therapeutics by 4.6% during the fourth quarter. Wellington Management Group LLP now owns 25,345,680 shares of the company’s stock worth $59,562,000 after purchasing an additional 1,125,454 shares during the period. FMR LLC increased its stake in shares of Autolus Therapeutics by 44.6% in the 3rd quarter. FMR LLC now owns 17,773,873 shares of the company’s stock valued at $64,519,000 after acquiring an additional 5,478,706 shares during the last quarter. Candriam S.C.A. acquired a new stake in shares of Autolus Therapeutics in the 4th quarter valued at approximately $7,500,000. JPMorgan Chase & Co. boosted its stake in Autolus Therapeutics by 145.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,284,708 shares of the company’s stock worth $4,663,000 after acquiring an additional 761,008 shares during the last quarter. Finally, BIT Capital GmbH grew its holdings in Autolus Therapeutics by 147.0% during the fourth quarter. BIT Capital GmbH now owns 636,979 shares of the company’s stock valued at $1,497,000 after purchasing an additional 379,050 shares during the period. Institutional investors and hedge funds own 72.83% of the company’s stock.

Autolus Therapeutics Price Performance

Shares of Autolus Therapeutics stock opened at $1.33 on Friday. The firm has a market cap of $353.91 million, a price-to-earnings ratio of -1.10 and a beta of 2.06. The stock’s 50-day moving average is $1.88 and its 200-day moving average is $2.74. Autolus Therapeutics plc has a one year low of $1.31 and a one year high of $5.70.

Autolus Therapeutics (NASDAQ:AUTL) last released its earnings results on Thursday, March 20th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.12. The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $2.98 million. On average, equities analysts expect that Autolus Therapeutics plc will post -0.94 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. Truist Financial cut their target price on shares of Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday. Needham & Company LLC reiterated a “buy” rating and set a $10.00 target price on shares of Autolus Therapeutics in a report on Monday, January 13th. Finally, Wells Fargo & Company lowered their price target on Autolus Therapeutics from $8.00 to $6.00 and set an “overweight” rating for the company in a report on Friday, March 21st. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $9.32.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.